A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
This Phase 3, 26-week, open label study with a 12-week, placebo-controlled, randomized withdrawal period followed by an open label long term safety extension will evaluate the safety and efficacy of tenapanor to treat hyperphosphatemia in end-stage renal disease (ESRD) on hemodialysis and peritoneal dialysis.
Epistemonikos ID: 03d8bb17b691aeaafb1d20281e12e8dde62026bb
First added on: May 21, 2024